  Oncolytic virotherapy - the use of viruses that specifically kill tumor cells
- is an innovative and highly promising route for treating cancer. However, its
therapeutic outcomes are mainly impaired by the host immune response to the
viral infection. In the present work, we propose a multiscale mathematical
model to study how the immune response interferes with the viral oncolytic
activity. The model assumes that cytotoxic T cells can induce apoptosis in
infected cancer cells and that free viruses can be inactivated by neutralizing
antibodies or cleared at a constant rate by the innate immune response. Our
simulations suggest that reprogramming the immune microenvironment in tumors
could substantially enhance the oncolytic virotherapy in immune-competent
hosts. Viable routes to such reprogramming are either in situ virus-mediated
impairing of CD$8^+$ T cells motility or blockade of B and T lymphocytes
recruitment. Our theoretical results can shed light on the design of viral
vectors or new protocols with neat potential impacts on the clinical practice.
